The spectrum of cutaneous adverse events during Encorafenib and Binimetinib treatment in BRAF mutant advanced melanoma

ConclusionCompared to data published for established BRAFi, encorafenib monotherapy showed less hyperproliferative cutaneous adverse events. In contrast, palmoplantar hyperkeratosis and palmoplantar erythrodysesthesia seem to occur more often. The combination encorafenib with binimetinib is well tolerated and induces few cutaneous adverse events.This article is protected by copyright. All rights reserved.

Source: Journal of the European Academy of Dermatology and Venereology - November 23, 2018 Category: Dermatology Authors: N.P. Graf, P. Koelblinger, N. Galliker, S. Conrad, M. Barysch, J. Mangana, R. Dummer, P.F. Cheng, S.M. Goldinger Tags: Original Article Source Type: research